Navigation Links
SGX Presents Preclinical MET Data at AACR
Date:4/15/2008

licated in human cancers including JAK2 and RAS. More information on the pipeline and drug discovery platform can be found at http://www.sgxpharma.com and in the Company's various filings with the Securities and Exchange Commission.

Forward Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include, but are not limited to, statements related to the Company's MET program and the advancement of the Company's drug development and discovery pipeline. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug discovery, development and commercialization, which include, without limitation, the potential failure of development candidates to advance through preclinical studies or demonstrate safety and efficacy in clinical testing and the ability to file INDs in the referenced time frames. The results of early preclinical studies or clinical trials may not be predictive of future results, and the Company cannot provide any assurances that any of its compounds or development candidates will have favorable results in preclinical studies or clinical trials. For a discussion of these and other factors, please refer to the risk factors described in the Company's annual report on Form 10-K for the year ended December 31, 2007, as well as other filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their en
'/>"/>

SOURCE SGX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
2. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
3. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health
4. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
5. Sangamo BioSciences Presents Data Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
6. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
7. Arpida Presents Preclinical Data on AR-2474 at ICAAC
8. Resverlogix Presents Key Apo-Al/HDL Scientific Data at DALM
9. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
10. BAI Retail Delivery Conference Softpro Presents Next Generation Signature Tablet
11. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... , March 2, 2015 VG ... developing therapies for autoimmune and infectious diseases, announced ... has issued an important new composition of matter ... through the targeting of CLIP. ... technology underlying VG Life Sciences, VG1177, a synthetic ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 Increasing its efforts ... Films launches its first three episodes of The GMO TRUTH ... Project this month, as it continues its mission to discover ... the project's first phase, to “uncover the truth about the ... media. , The GMO Truth Podcast is an expansion of ...
(Date:2/27/2015)... DUBLIN , Feb. 27, 2015 Research and Markets ... the "Global Market Report of Trypsin" report to ... Trypsin (CAS 9002-07-7) aims at providing comprehensive data on Trypsin ... Asia , North America , ... trends, pays close attention to Trypsin This report ...
(Date:2/27/2015)... Illinois (PRWEB) February 27, 2015 FamilyFarms ... Sims, General Manager of State Line Farms, received the ... recognizes a producer, under the age of 35, who ... "It is an honor to win the Tomorrow's Top ... discovering who won the Top Producer Award and learning ...
Breaking Biology Technology:VG Life Sciences Granted Key Composition Of Matter Patent 2VG Life Sciences Granted Key Composition Of Matter Patent 3The Walk a Mile Project Launches “GMO Truth” Podcast 2Global Market Report of Trypsin 2014-2018 2Matt Sims Receives the 2015 Tomorrow’s Top Producer Horizon Award 2
... induce stress,but caring for children with diabetes this time ... and caregivers can visit, http://www.abbottdiabetescare.com to participate in ... how to best manage a child,s,diabetes during the holidays, ... ,Diabetes Fit Food, booklet for tips on healthy eating. ...
... REDWOOD CITY, Calif., Nov. 7 Threshold,Pharmaceuticals, Inc. ... for,the third quarter ended September 30, 2007. Net ... million compared to $16.7 million for the third ... development of our hypoxia-activated prodrug,platform for the treatment ...
... 13 at 1:30 p.m. (Pacific); ... at http://www.adventrx.com , SAN DIEGO, Nov. 7 ... research and development company,focused on commercializing proprietary product candidates ... financial results for,the three-month and nine-month periods ended September ...
Cached Biology Technology:New Web Site Tools Help Alleviate Stress Associated with Caring for Children with Diabetes During the Holidays 2Threshold Pharmaceuticals Reports Third Quarter 2007 Financial Results 2Threshold Pharmaceuticals Reports Third Quarter 2007 Financial Results 3Threshold Pharmaceuticals Reports Third Quarter 2007 Financial Results 4Threshold Pharmaceuticals Reports Third Quarter 2007 Financial Results 5ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results 2ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results 3ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results 4ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results 5ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results 6ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results 7
(Date:3/2/2015)... Ala. , March 2, 2015  Businesses ... processing. Data protection company Tharon Rankins Enterprises has ... that provides an ultra-safe way for businesses to ... their financial transactions. Beconux is ... Tharon Rankins Enterprises. Functioning similarly to an ATM ...
(Date:2/24/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/sxwl43/global_2d_gesture ) ... 2D Gesture Recognition Market 2015-2019" report to ... the Global 2D Gesture Recognition market to grow ... 2014-2019 The increased demand for gesture-enabled ... the major trends in the market. The growing ...
(Date:2/12/2015)...   MedNet Solutions , a global life ... systems, has recently bolstered its iMedNet™ ... iMedNet as the eClinical solution of ... consultants.  Building on the Program,s existing benefits (including ... co-marketing opportunities), MedNet,s new and improved program provides ...
Breaking Biology News(10 mins):Personal Data Protection Company Launches New Product 2Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2
... type of brain cancer, undergo neurosurgery to remove the ... largely on how rapidly the cancer recurs. Even though ... it is difficult to determine with certainty whether cancer ... aggressive treatment. Now a team from the University ...
... ACTON, Mass., Jan. 24, 2012 Psychemedics Corporation (NASDAQ: ... global leader for 25 years, announced today that the ... No. 8,084,215, to the company.  This patent focuses on ... without destroying the drugs.  The new patented method can ...
... 23, 2012) - With growing concern that excessive levels of ... pressure, kidney disease and diabetes researchers at the University of ... of Florida, set out to see if two common sweeteners in ... first few hours after ingestion. The study, recently published in ...
Cached Biology News:Team finds new way to image brain tumors and predict recurrence 2Psychemedics Awarded Patent Fundamental To Hair Analysis Drug Testing 2CU School of Medicine researchers look at effects of 2 common sweeteners on the body 2
The product contains 2 ml Dynabeads® Epoxy (4.5 μm). Supplied at 4 x 10e8 beads/ml...
PFK-2 car (P-17)...
... ml Dynabeads Epoxy (4.5 m). Hydrophobic ... groups. Ideal for coupling of antibodies for ... initial coupling with covalent binding of primary ... groups (SH)) occurring within 16-20 hours. Coupling ...
LTBP-2 (7B10)...
Biology Products: